Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study

Kim, Sue Youn; Yun, Jae Moon; Lee, Ji Won; Cho, Young Gyu; Cho, Kyung-Hwan; Park, Yong Gyu; Cho, Belong

doi:10.1016/j.clinthera.2021.08.001

Cited by 8 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of interest, the weight gaining effect of cyproheptadine was likely due to its stimulation of hunger which suggested the central serotonergic mechanism of drug. The recent double-blind, placebo-controlled randomized trial by Kim et al,(Kim et al, 2021) included healthy adults with poor appetite. The study reported that there were significant increases in body weight and BMI after the 8-week administration of 3 mg cyproheptadine.…”

Section: Resultsmentioning

confidence: 99%

A Retrospective Study of Body Weight Changes in Patients Receiving Cyproheptadine in A Hospital-Based Outpatient Setting in Thailand

Chansane,

Suntornsantoon,

Chaiyapak

et al. 2023

Indonesian J Pharm

View full text Add to dashboard Cite

Cyproheptadine has been used as an appetite stimulant to increase body weight in various population. This study aimed to determine the effect of cyproheptadine on weight changes in Thai patients. A retrospective longitudinal study was conducted in adult patients who were prescribed with cyproheptadine, having body weight records at 2 times consecutively during 12-month period at the medical outpatient department, the Police General Hospital, Thailand. Of 125 participants, 69.6% were females and the mean age was 78.38 (SD ± 11.68) years. Hypertension, dyslipidemia and diabetes mellitus were the most common underlying conditions. The mean body mass index (BMI) at 1st visit was 21.16 (SD ± 3.64) kg/m2. The mean body weight at 1st and 2nd visit were 52.46 (SD ± 11.11) kg, and 52.61 (SD ± 10.98) kg, respectively. Overall, there was no significant change in body weight between two visits. In underweight patients (BMI < 18.5 kg/m2), the mean BMI decreased significantly in the 2nd visit compared to 1st visit (p = 0.044). At the 2nd visit, older age and high-density lipoprotein cholesterol levels were negatively associated with body weight (p < 0.05). The polypharmacy (odds ratio (OR), 0.778; 95% confidence interval (CI), 0.616 – 0.982), the presence of hypertension (OR, 0.022; 95%. CI, 0.001 – 0.390) and low-density lipoprotein cholesterol levels (OR, 0.969; 95% CI, 0.942 – 0.996) were also negatively associated with abnormal BMI. Cyproheptadine might not improve the body weight of patients in this population. The factors associated with lower body weight in this study may be helpful in further research.

show abstract

Section: Resultsmentioning

confidence: 99%

A Retrospective Study of Body Weight Changes in Patients Receiving Cyproheptadine in A Hospital-Based Outpatient Setting in Thailand

Chansane,

Suntornsantoon,

Chaiyapak

et al. 2023

Indonesian J Pharm

View full text Add to dashboard Cite

show abstract

“…Appetite stimulation [17,18] A safe, generally well-tolerated medication that facilitates weight gain in patients from a variety of underweight populations.…”

Section: Evidence Based On Recent Studiesmentioning

confidence: 99%

“…Therefore, it is imperative to make inquiries into these complex relationships, risks, and benefits of off-label cyproheptadine use in children and adolescents with cooccurring mental health conditions. Cyproheptadine has an affinity for a wide range of receptors [14][15][16][17][18][19][20][21][22] and many proposed mechanisms of action to support its off-label use [23][24][25][26][27][28].…”

Section: Introductionmentioning

confidence: 99%

Off-Label Cyproheptadine in Children and Adolescents: Psychiatric Comorbidities, Interacting Variables, Safety, and Risks of Hepatotoxicity

Gupta¹,

Gupta²,

Madabushi³

2023

Cureus

View full text Add to dashboard Cite

Cyproheptadine is a widely prescribed first-generation antihistamine, and due to its unique chemical structure, it has a popular off-label choice for a range of clinical conditions. Its efficacy is widely debated in the literature, but there are reports of hepatotoxicity as a rare adverse effect. Its benefits in migraine prophylaxis and appetite stimulation also underscore a highly overlapping clinical pathway that requires additional assessment and evaluation. The evidence suggests a baseline metabolic profile before initiation and assessment for co-occurring mental health conditions may improve overall response with evidencebased mental health interventions.

show abstract

“…It was first introduced to treat allergic conditions, but for the past two decades, research has focused on its efficacy in increasing appetite and its direct effects on weight (Harrison et al, 2019). In surveys, it is also reported to have an effect on the linear growth of individuals under 12 years of age, which leads to a growth process that implies a continuous increase in high dimensional measurements for a constant period (Kim et al, 2021). This drug has been used in studies evaluating its efficacy by focusing on specific disease groups with marked weight loss due to disease progression (Pais, 2019).…”

Section: Introductionmentioning

confidence: 99%

Cyproheptadine as an appetite stimulant in children. Is it safe?

Philco Toaza

2023

SIJIS

View full text Add to dashboard Cite

Background: Cyproheptadine as an appetite stimulant in children. Is it safe? This drug has been used to increase appetite in pediatric patients, regardless of their sex or the presence of pathological conditions. The effectiveness of this drug in terms of weight gain and growth is still a matter of interest. due to the diversity of conclusions regarding its mechanism of action and therapeutic results. Methods: This bibliographic review of the scientific literature focused on research in order to obtain results around scientific articles related to the use of cyproheptadine as an appetite stimulant in pediatric patients. Results: all the articles analyzed concluded that cyproheptadine is an effective medication for weight gain in pediatric patients, based on appetite stimulation, totally independent of sex and the presence of pathological states. Conclusions: Cyproheptadine is a safe medication, and adequately tolerated in all pediatric patients. It is possible to measure the improvement in weight and growth indices in patients under twelve years of age, if consumption is for at least four consecutive weeks.

show abstract

Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study

Cited by 8 publications

References 20 publications

A Retrospective Study of Body Weight Changes in Patients Receiving Cyproheptadine in A Hospital-Based Outpatient Setting in Thailand

A Retrospective Study of Body Weight Changes in Patients Receiving Cyproheptadine in A Hospital-Based Outpatient Setting in Thailand

Off-Label Cyproheptadine in Children and Adolescents: Psychiatric Comorbidities, Interacting Variables, Safety, and Risks of Hepatotoxicity

Cyproheptadine as an appetite stimulant in children. Is it safe?

Contact Info

Product

Resources

About